Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNS812 in Mild to Moderate COVID-19
NCT05941793Phase 2Completed
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of SNS812 in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Oneness Biotech Co., Ltd. Primary endpoint: Incidence and severity of Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events, and Serious Adverse Events (SAEs) at 2 months. Started Sep 2023; status: completed.
02
Drugs
SNS812
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05941793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941793.